Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2008. For the three-month period, the Company posted revenue of $1.2 million and a net loss of $5.4 million. Cash and cash equivalents totaled $14.3 million at September 30, 2008.

"The past several months have been extremely productive as we further our transition to a development-only company," said Ev Graham, acting Chief Executive Officer of TorreyPines Therapeutics. "We held a successful End of Phase II meeting with the U.S. Food & Drug Administration (FDA) for tezampanel and believe we are well positioned to seek a corporate partner to continue its development. In addition, we continued to execute on our strategic plan by completing three transactions involving some of the Company's non-core assets. Looking ahead, we are on track to announce results from two clinical trials by the end of the year."

Upcoming Clinical Milestones:

-- Results from a Phase I clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of tezampanel, are on schedule to be announced in December 2008. The study is designed to evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli, when induced by intradermal injections of capsaicin.

-- Results from a Phase IIa study evaluating NGX267, a muscarinic agonist, as a potential treatment for xerostomia, are on schedule to be announced in December 2008. This study is designed to evaluate three doses of NGX267 and placebo in a four-way cross-over design in patients with xerostomia secondary to Sjogren's syndrome. The focus
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
2. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
3. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
4. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
7. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
8. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
9. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
10. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
11. TorreyPines Therapeutics Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... DIEGO, Aug. 13 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ... Institutional,Shareholder Services (ISS), two leading proxy advisory firms, have,recommended ... Eli,Lilly and Company (NYSE: LLY ) at the ... for August 20, 2008., The Board of Directors ...
... for Hepatitis B, as well as HIV-1 ... -, SAN DIEGO, Aug. 13 Gen-Probe Incorporated,(Nasdaq: ... and Drug Administration,(FDA) has approved its supplemental regulatory application ... for the hepatitis B,virus (HBV). The FDA had previously ...
... 13 Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of ... creditors, announced today that all pharmaceutical,intellectual property will be ... One of the pieces of intellectual property for ... a branded drug that currently has,more than $2 billion ...
Cached Biology Technology:SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4
(Date:5/23/2013)... Northwest National Laboratory honored more than 165 staff ... property at PNNL,s annual Intellectual Property Commercialization Recognition ... of Energy national laboratory named materials scientist Jun ... developing battery materials that can store large amounts ... and reduce the time it takes to charge ...
(Date:5/23/2013)... overall health, development, and academic success of children, ... that all students have opportunities to engage in ... or moderate-intensity physical activity, says a new report ... suggest that only about half of school-age children ... and development. The report recommends that most ...
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... human health, continuously prowling the body and registering ... astonishing acuity. They also serve as biochemical memory ... and efficiently storing this data for later use. ... colleagues at the Biodesign Institute at Arizona State ...
... IQ scores are used to assess the intelligence of ... "Social-IQ score" for bacteria ― and it may lead ... the agricultural industry. An international team led by ... Physics and Astronomy and his research student Alexandra Sirota-Madi ...
... researchers and the public have a new way to ... Knowledge Discovery Framework, or KDF, developed by a team ... Department of Energy. The new site ( https://bioenergykdf.net ... technical data and a list of experts to the ...
Cached Biology News:Research into synthetic antibodies offers hope for new diagnostics 2Research into synthetic antibodies offers hope for new diagnostics 3Research into synthetic antibodies offers hope for new diagnostics 4The genius of bacteria 2New DOE bioenergy website has ORNL roots 2
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
Biology Products: